Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 629 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: quinolone Clear all

Conditions: Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions: AZD0914, Moxifloxacin, Placebo; Drug · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Volunteer
Interventions: Moxifloxacin, RO4917838, RO4917838 placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 169 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Pregnancy
Interventions: ciprofloxacin, azithromycin, gentamicin; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Dexpramipexole, Dexpramipexole Placebo, Moxifloxacin; Drug
Lead sponsor: Knopp Biosciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Acute Otitis Externa
Interventions: FST-201 (dexamethasone 0.1%) Otic Suspension, ciprofloxacin 0.3%, dexamethasone 0.1%; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Boynton Beach, Florida • Sarasota, Florida • Austin, Texas + 1 more

Conditions: Schizophrenia
Interventions: Paliperidone extended release (ER), Aripiprazole; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Dothan, Alabama • Santa Ana, California • Atlanta, Georgia + 3 more

Conditions: Bladder Carcinoma, Refractory Bladder Carcinoma, Urinary Tract Infection
Interventions: Clindamycin, Diary, Ertapenem, Levofloxacin, Nitrofurantoin, Trimethoprim-Sulfamethoxazole; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy Volunteers
Interventions: Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Cystic Fibrosis
Interventions: Lumacaftor, Ivacaftor, Ciprofloxacin, Itraconazole, Rifampin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2013
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: OPC-34712 (4mg), Moxifloxacin, OPC-34712 (12mg), Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Long Beach, California • San Diego, California • Fort Lauderdale, Florida + 5 more

Conditions: Cholangitis
Interventions: Ceftriaxone, Levofloxacin; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Schizophrenia
Interventions: Cariprazine, Aripiprazole, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 17 more

Conditions: Healthy Volunteers
Interventions: BMS-986419, BMS-986419 Matching Placebo, Moxifloxacin, Moxifloxacin Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
Interventions: Aripiprazole + IEM (Ingestible Event Marker); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Granada Hills, California • Rochester, New York • Durham, North Carolina + 1 more

Conditions: Acute Otitis Externa
Interventions: Ciprodex®, EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension; Drug
Lead sponsor: Exela Pharma Sciences, LLC.; Industry
Eligibility: 6 Months and older
Enrollment: 499 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 46
States / cities: Birmingham, Alabama • Mesa, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Schizophrenia
Interventions: Aripiprazole, Risperidone; Drug
Lead sponsor: Northwell Health; Other
Eligibility: 15 Years to 40 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Glen Oaks, New York

Conditions: Healthy
Interventions: Ulonivirine, Moxifloxacin, Ulonivirine Placebo, Moxifloxacin Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Bipolar I Disorder
Interventions: Injectable Risperidone (Consta) or oral antipsychotic; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 4
States / cities: Bridgeville, Pennsylvania • DuBois, Pennsylvania • McKeesport, Pennsylvania + 1 more

Conditions: RSV Infection, QTc Interval
Interventions: zelicapavir (therapeutic dose), zelicapavir (supratherapeutic dose), Placebo, moxifloxacin; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Lenexa, Kansas • San Antonio, Texas

Conditions: Healthy
Interventions: TRV130, Moxifloxacin, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis
Interventions: Ciprofloxacin (Cipro Inhale, BAYQ3939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 12 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 58
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 47 more

Conditions: Bipolar I Disorder
Interventions: Aripiprazole, Placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 40
States / cities: Mesa, Arizona • La Mesa, California • La Palma, California + 37 more

Conditions: Bipolar Disorder
Interventions: Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: Not listed
Enrollment: 1,037,352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

A Study of the Effect of RO4917838 on the QTcF Interval in Healthy Volunteers

Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

Study to Evaluate the QTC Interval in Healthy Volunteers Dosed With Dexpramipexole (QTC = Electrocardiogram (ECG) Interval Measured From the Onset of the QRS Complex to the End of the T Wave Corrected for Heart Rate)

FST-201 In The Treatment of Acute Otitis Externa

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

Prophylactic Antibiotics for Urinary Tract Infections After Robot-Assisted Radical Cystectomy

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects

Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder

Antibiotics to Decrease Post ERCP Cholangitis

Safety and Efficacy of Cariprazine in Patients With Schizophrenia

A Study to Investigate the Safety, Tolerability, and Drug Levels of BMS-986419 (Part 1) and the Effects Multiple Doses of BMS-986419 on Cardiac Repolarization (Part 2) in Healthy Participants

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System

Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

Risperdal Consta for Bipolar Disorder

A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies